<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05045781</url>
  </required_header>
  <id_info>
    <org_study_id>19004A</org_study_id>
    <nct_id>NCT05045781</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects</brief_title>
  <official_title>Interventional, Single-ascending-dose Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Eptinezumab in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate how the body absorbs and get rid of eptinezumab&#xD;
      when given directly into a vein in Chinese subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an interventional, randomized, open-label, parallel-group, single-dose study&#xD;
      investigating the safety, tolerability and pharmacokinetic properties of eptinezumab&#xD;
      administered by intravenous (iv) infusion.&#xD;
&#xD;
      The study will consist of 20 healthy Chinese subjects, who will be randomized into two&#xD;
      single-dose groups. The two groups will be run in parallel. In Group 1, a total of 10&#xD;
      subjects will receive a single iv infusion of 100 mg eptinezumab on Day 1. In Group 2, a&#xD;
      total of 10 subjects will receive a single iv infusion of 300 mg eptinezumab on Day 1.&#xD;
&#xD;
      Safety and tolerability will be assessed throughout the study. Blood samples for plasma&#xD;
      quantification of free eptinezumab will be collected from Day 1 to the Completion Visit (Day&#xD;
      84)/Withdrawal Visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Actual">July 20, 2021</completion_date>
  <primary_completion_date type="Actual">July 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC(0-inf) eptinezumab</measure>
    <time_frame>Day 1 to Day 84</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximal observed plasma concentration (Cmax) of eptinezumab</measure>
    <time_frame>Day 1 to Day 84</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic clearance (CL) of eptinezumab</measure>
    <time_frame>Day 1 to Day 84</time_frame>
    <description>Eptinezumab dose/AUC(0-inf)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax</measure>
    <time_frame>Day 1 to Day 84</time_frame>
    <description>Nominal time for the occurrence of Cmax (tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t½)</measure>
    <time_frame>Day 1 to Day 84</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Eptinezumab 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Eptinezumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eptinezumab</intervention_name>
    <description>single iv infusion</description>
    <arm_group_label>Eptinezumab 100 mg</arm_group_label>
    <arm_group_label>Eptinezumab 300 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI of ≥ 19 and ≤ 25 kg/m2.&#xD;
&#xD;
          -  The subject is Chinese, defined as being born in China and having four Chinese&#xD;
             grandparents.&#xD;
&#xD;
          -  The subject is, in the opinion of the investigator, generally healthy based on medical&#xD;
             history, a physical examination, vital signs, an ECG, and the results of the clinical&#xD;
             chemistry, haematology, urinalysis, serology, and other laboratory tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is pregnant or breastfeeding.&#xD;
&#xD;
          -  The subject has or has had any clinically significant immunological, cardiovascular,&#xD;
             respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological,&#xD;
             haematological, dermatological, venereal, neurological, or psychiatric disease or&#xD;
             other major disorder.&#xD;
&#xD;
        Other inclusion and exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>zs-hospital Shanghai</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

